Holen Sie sich die Stockscreener-App
1.23
1.60%
-0.02
Aditxt Inc Aktie (ADTX) Neueste Nachrichten
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting - Benzinga
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board - citybiz
Aditxt Inc. Strengthens Board with Appointment of Evofem CEO Saundra Pelletier - citybuzz -
Aditxt names Evofem CEO to its board, eyes women’s health market By Investing.com - Investing.com South Africa
Aditxt names Evofem CEO to its board, eyes women’s health market - Investing.com India
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board Of Directors - MarketScreener
Aditxt (ADTX) Welcomes Saundra Pelletier to Its Board | ADTX Stock News - GuruFocus
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors | ADTX Stock News - GuruFocus
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors - Business Wire
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, - GuruFocus
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO Of Adimune, And Chris Mitton, President Of Pearsanta, Will Join Aditxt Weekly Update On June 6 - MarketScreener
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 - Bluefield Daily Telegraph
Healthcare Innovation Leaders From Evofem, Adimune, and Pearsanta Preview New Developments at Aditxt Update - Stock Titan
Aditxt (NASDAQ:ADTX) Shares Down 8.1% – Time to Sell? - Defense World
Aditxt Highlights Strategic Partnership with Evofem Biosciences - TipRanks
ADTX stock plunges to 52-week low, touches $1.5 amid steep decline By Investing.com - Investing.com South Africa
ADTX stock plunges to 52-week low, touches $1.5 amid steep decline - Investing.com Nigeria
Stocks In Play: Appili Therapeutics Inc. By Baystreet.ca - Investing.com Canada
Appili Therapeutics Inc. - Baystreet.ca
Appili Therapeutics Ends Agreement with Aditxt, Secures Loan Extensions - TipRanks
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. - The Manila Times
Options Volatility and Implied Earnings Moves Today, May 29, 2025 - The Globe and Mail
Aditxt secures $233K loan from CEO Albanna - Investing.com Australia
Aditxt secures $233K loan from CEO Albanna By Investing.com - Investing.com South Africa
Aditxt Issues Unsecured Promissory Note in Strategic Move - TipRanks
Aditxt (ADTX) Cancels Acquisition Agreement with Appili Therapeu - GuruFocus
Aditxt Discusses Strategic Focus and Growth Plans - TipRanks
Aditxt to Scrap Merger Deal With Appili Therapeutics - marketscreener.com
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics | ADTX Stock News - GuruFocus
Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics - marketscreener.com
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - The Manila Times
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Eagle-Tribune
Aditxt, Inc. SEC 10-Q Report - TradingView
Aditxt (NASDAQ:ADTX) Shares Down 5.5% – What’s Next? - Defense World
Aditxt Highlights Progress of ADI-100TM in Autoimmune Treatment - TipRanks
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Quantisnow
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, - GuruFocus
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department - GuruFocus
Aditxt secures $256K through senior note sales By Investing.com - Investing.com Nigeria
Aditxt secures $256K through senior note sales - Investing.com
Aditxt’s Subsidiary Pearsanta Gets IRB Approval - TipRanks
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):